FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 314:1006-1010 April 17, 1986 Number 16 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

In an attempt to prevent primary cytomegalovirus infection after marrow transplantation, we randomly assigned 97 patients who were seronegative for antibody to cytomegalovirus before transplantation to receive one of the following: (1) both intravenous cytomegalovirus immune globulin and seronegative blood products (23 patients); (2) seronegative blood products alone (28 patients); (3) globulin alone (22 patients); or (4) neither treatment (24 patients). Patients not assigned to receive seronegative blood products received unscreened blood products from random donors. The incidence of cytomegalovirus infection according to study group among patients in the study for at least 62 days was 5 percent, 13 percent, 24 percent, and 40 percent, respectively. Among 57 patients with seronegative marrow donors, those who received seronegative blood products had significantly less infection (1 of 32) than those who received standard blood products (8 of 25, P less than 0.007). In contrast, the use of seronegative blood products did not appear to prevent cytomegalovirus infection among patients with seropositive marrow donors. The possibility that cytomegalovirus immune globulin as used in this study can prevent cytomegalovirus infection or ameliorate cytomegalovirus disease was not confirmed, and it cannot be recommended for routine use without additional study.

This article has been cited by other articles:

• Boeckh, M., Ljungman, P. (2009). How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113: 5711-5719 [Abstract] [Full Text]  
• Raanani, P., Gafter-Gvili, A., Paul, M., Ben-Bassat, I., Leibovici, L., Shpilberg, O. (2009). Immunoglobulin Prophylaxis in Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. JCO 27: 770-781 [Abstract] [Full Text]  
• Ljungman, P., Brand, R. (2007). Factors influencing CMV seropositivity in stem cell transplant patients and donors. haematol 92: 1139-1142 [Abstract] [Full Text]  
• Sandherr, M., Einsele, H., Hebart, H., Kahl, C., Kern, W., Kiehl, M., Massenkeil, G., Penack, O., Schiel, X., Schuettrumpf, S., Ullmann, A. J., Cornely, O. A. (2006). Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 17: 1051-1059 [Abstract] [Full Text]  
• Raghavan, M., Marik, P. E. (2005). Anemia, Allogenic Blood Transfusion, and Immunomodulation in the Critically Ill. Chest 127: 295-307 [Abstract] [Full Text]  
• Boeckh, M., Nichols, W. G. (2004). The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103: 2003-2008 [Abstract] [Full Text]  
• Cordonnier, C., Chevret, S., Legrand, M., Rafi, H., Dhedin, N., Lehmann, B., Bassompierre, F., Gluckman, E., for the GREFIG Study Group*, (2003). Should Immunoglobulin Therapy Be Used in Allogeneic Stem-Cell Transplantation? A Randomized, Double-Blind, Dose Effect, Placebo-Controlled, Multicenter Trial. ANN INTERN MED 139: 8-18 [Abstract] [Full Text]  
• Nichols, W. G., Price, T. H., Gooley, T., Corey, L., Boeckh, M. (2003). Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 101: 4195-4200 [Abstract] [Full Text]  
• Tabbara, I. A., Zimmerman, K., Morgan, C., Nahleh, Z. (2002). Allogeneic Hematopoietic Stem Cell Transplantation: Complications and Results. Arch Intern Med 162: 1558-1566 [Abstract] [Full Text]  
• Dumont, L. J., Luka, J., VandenBroeke, T., Whitley, P., Ambruso, D. R., Elfath, M. D. (2001). The effect of leukocyte-reduction method on the amount of human cytomegalovirus in blood products: a comparison of apheresis and filtration methods. Blood 97: 3640-3647 [Abstract] [Full Text]  
• (2000). Management of herpes virus infections following transplantation. J Antimicrob Chemother 45: 729-748 [Full Text]  
• Strauss, R. G. (2000). Transfusion Approach to Neonatal Anemia. NeoReviews 1: e74-80 [Full Text]  
• Zhuravskaya, T., Maciejewski, J.P., Netski, D.M., Bruening, E., Mackintosh, F.R., St Jeor, S. (1997). Spread of Human Cytomegalovirus (HCMV) After Infection of Human Hematopoietic Progenitor Cells: Model of HCMV Latency. Blood 90: 2482-2491 [Abstract] [Full Text]  
• Walters, M. C., Patience, M., Leisenring, W., Eckman, J. R., Scott, J. P., Mentzer, W. C., Davies, S. C., Ohene-Frempong, K., Bernaudin, F., Matthews, D. C., Storb, R., Sullivan, K. M. (1996). Bone Marrow Transplantation for Sickle Cell Disease. NEJM 335: 369-376 [Abstract] [Full Text]  
• Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D., Riddell, S. R. (1995). Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor. NEJM 333: 1038-1044 [Abstract] [Full Text]  
• Armitage, J. O. (1994). Bone Marrow Transplantation. NEJM 330: 827-838 [Full Text]  
• Shelhamer, J. H., Toews, G. B., Masur, H., Suffredini, A. F., Pizzo, P. A., Walsh, T. J., Henderson, D. K. (1992). Respiratory Disease in the Immunosuppressed Patient. ANN INTERN MED 117: 415-431 [Abstract]  
• Sayers, M. H., Anderson, K. C., Goodnough, L. T., Kurtz, S. R., Lane, T. A., Pisciotto, P., Silberstein, L. E. (1992). Reducing the Risk for Transfusion-transmitted Cytomegalovirus Infection. ANN INTERN MED 116: 55-62 [Abstract]  
• Wong, T., Toupance, O., Chanard, J. (1991). Acyclovir To Prevent Cytomegalovirus Infection after Renal Transplantation. ANN INTERN MED 115: 68-68 [Abstract]  
• Louie, S. G., Jaresko, G. S. (1991). Biological Agents in Infectious Diseases. Journal of Pharmacy Practice 4: 326-341 [Abstract]  
• Berkman, S. A., Lee, M. L., Gale, R. P. (1990). Clinical Uses of Intravenous Immunoglobulins. ANN INTERN MED 112: 278-292 [Abstract]  
• Kasiske, B. L., Heim-Duthoy, K. L., Tortorice, K. L., Ney, A. L., Odland, M. D., Rao, K. V. (1989). Polyvalent Immune Globulin and Cytomegalovirus Infection After Renal Transplantation. Arch Intern Med 149: 2733-2736 [Abstract]  
• Stratta, R. J., Shaefer, M. S., Markin, R. S., Wood, R. P., Kennedy, E. M., Langnas, A. N., Reed, E. C., Woods, G. L., Donovan, J. P., Pillen, T. J., Duckworth, R. M., Shaw, B. W. Jr (1989). Clinical Patterns of Cytomegalovirus Disease After Liver Transplantation. Arch Surg 124: 1443-1450 [Abstract]  
• Emanuel, D., Cunningham, I., Jules-Elysee, K., Brochstein, J. A., Kernan, N. A., Laver, J., Stover, D., White, D. A., Fels, A., Polsky, B., Castro-Malaspina, H., Peppard, J. R., Bartus, P., Hammerling, U., O'Reilly, R. J. (1988). Cytomegalovirus Pneumonia after Bone Marrow Transplantation Successfully Treated with the Combination of Ganciclovir and High-Dose Intravenous Immune Globulin. ANN INTERN MED 109: 777-782 [Abstract]  
• Shannon, K. M., Cowan, M. J., Matthay, K. K. (1987). Pediatric Bone Marrow Transplantation: Intensive Care Management. J Intensive Care Med 2: 328-344 [Abstract]  
• STIEHM, E. R., ASHIDA, E., KIM, K. S., WINSTON, D. J., HAAS, A., GALE, R. P. (1987). Intravenous Immunoglobulins as Therapeutic Agents. ANN INTERN MED 107: 367-382 [Abstract]  
• WINSTON, D. J., HO, W. G., LIN, C.-H., BARTONI, K., BUDINGER, M. D., GALE, R. P., CHAMPLIN, R. E. (1987). Intravenous Immune Globulin for Prevention of Cytomegalovirus Infection and Interstitial Pneumonia After Bone Marrow Transplantation. ANN INTERN MED 106: 12-18 [Abstract]  
• Thomas, E.D. (1986). Marrow Transplantation and Gene Transfer as Therapy for Hematopoietic Diseases. Cold Spring Harb Symp Quant Biol 51: 1009-1012 [Abstract]